Morgan Stanley Upgrades MorphoSys to Overweight, Raises Price Target to $9.2
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst James Quigley has upgraded MorphoSys (NASDAQ:MOR) from Underweight to Overweight and raised the price target from $3.7 to $9.2.
October 13, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has upgraded MorphoSys from Underweight to Overweight and raised the price target from $3.7 to $9.2.
The upgrade from Morgan Stanley is a positive signal for MorphoSys. The increase in price target indicates that the analyst sees potential for the stock's price to rise significantly. This could lead to increased investor interest and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100